The Variation of Platelet Function in Gestational Diabetes Mellitus.

Abstract Gestational diabetes mellitus (GDM) was as glucose intolerance of different severity that onset or first recognition during the current pregnancy. GDM was a special complication of pregency and the most common cause of fetal and maternal mortality and morbidity. The etiology of this disease is not clear. Increased platelet function was common in normal pregnancy or type 2 diabetes mellitus (DM) patients in the last decade. However, when pregnancy plus type 2 DM, that is, the GDM, was the platelet function still changed? In the current study, we tested blood platelet function including platelet counts (PC), mean platelet volume (MPV) and granule membrane protein-140 (GMP-140, also known as P-selectin, CD62P) in pregnant women with GDM. CD62P was a sensitive index to evaluate platelet activation. PC and MPV would alter when platelets had been destructed significantly, so they were sensitive indexes for platelet activation too. PC was (206.02±60.23)×109/L in GDM, (228.76±56.24)×109/L in normal pregnancy, (219.76±58.14)×109/L in type 2 DM without pregnancy. MPV was 9.53±1.64fl in GDM, 8.74±1.59fl in normal pregnancy, 9.16±1.23fl in type 2 DM without pregnancy. The PC and MPV had no significant difference among GDM, normal pregnancy and type 2 DM without pregnancy (P>0.05). The expression of CD62P was higher than that of normal pregnancy or type 2 DM (41.82±12.95% vs. 26.21±7.09% or 24.18±8.79% P<0.05). These results indicate that there were much more platelet activation in GDM compared with normal pregnancy or type 2 DM, but the platelet destruction was not increased. Inhibition of activated platelet may be a new therapeutic strategy for the treatment of GDM. However, whether there was special role affecting platelet activation directly in GDM was unknown. The concrete mechanism underlying GDM platelet dysfunction need more elucidated.

Download Full-text

Alterations in lipid profile in gestational diabetes mellitus (GDM) and type 2 DM women during pregnancy

International Journal of Medical Research and Review ◽

10.17511/ijmrr.2015.i8.150 ◽

2015 ◽

Vol 3 (8) ◽

pp. 800-804

Author(s):

Dr. K. Vani ◽

Keyword(s):

Diabetes Mellitus ◽

Gestational Diabetes ◽

Gestational Diabetes Mellitus ◽

Lipid Profile ◽

Type 2 Dm

Download Full-text

Previous Gestational Diabetes Mellitus and Markers of Cardiovascular Risk

International Journal of Endocrinology ◽

10.1155/2012/458610 ◽

2012 ◽

Vol 2012 ◽

pp. 1-6 ◽

Cited By ~ 32

Author(s):

Nikolaos Vrachnis ◽

Areti Augoulea ◽

Zoe Iliodromiti ◽

Irene Lambrinoudaki ◽

Stavros Sifakis ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Gestational Diabetes ◽

Gestational Diabetes Mellitus ◽

Current Knowledge ◽

Normal Pregnancy ◽

Metabolic Abnormalities ◽

Cvd Risk ◽

Maternal Complications

The prevalence of gestational diabetes mellitus (GDM) in the developed world has increased at an alarming rate over the last few decades. GDM has been shown to be associated with postpartum diabetes, insulin resistance, hypertension, and dyslipidemia. A history of previous GDM (pGDM), associated or not with any of these metabolic abnormalities, can increase the risk of developing not only type 2 diabetes mellitus but also cardiovascular disease (CVD) independent of a diagnosis of type 2 diabetes later in life. In this paper we discuss the relationship among inflammatory markers, metabolic abnormalities, and vascular dysfunction in women with pGDM. We also review the current knowledge on metabolic modifications occurring in normal pregnancy and the link between alterations of a normal metabolic state with the long-term maternal complications that may result in increased CVD risk. Our review of studies on pGDM prompts us to recommend that these women be considered a population at risk for later CVD events, which however could be avoided via the use of specially designed follow-up programs in the future.

Download Full-text

GESTATIONAL DIABETES MELLITUS

Journal of Saidu Medical College, Swat ◽

10.52206/jsmc.2016.6.2.779-780 ◽

2018 ◽

Vol 6 (2) ◽

pp. 779-780

Author(s):

Aziz Ahmad

Keyword(s):

Diabetes Mellitus ◽

Gestational Diabetes ◽

Gestational Diabetes Mellitus ◽

Middle Income ◽

Middle Income Countries ◽

Type 2 Dm ◽

The World

The world is currently facing a global epidemicof Diabetes Mellitus (DM).WHO estimates thatpresently more than 418 million, about one inten adults people, are suffering from thismetabolic disorder worldwide and the projectedfigure for 2040 is exceeding 600 million,about70% in low-& middle income countries. Indiais the world capital with 50-60 million, followedby China with 45 million with largest age group40-59 years 1. Type 2 DM is the most commonform with incidence of 85-95%.

Download Full-text

SUN-639 Secretagogin Levels Are Unrelated to Gestational Diabetes Mellitus in a Cohort of Pregnant Women

Journal of the Endocrine Society ◽

10.1210/jendso/bvaa046.1764 ◽

2020 ◽

Vol 4 (Supplement_1) ◽

Author(s):

Carola Deischinger ◽

Jürgen Harreiter ◽

Ludwig Wagner ◽

Sabina Baumgartner-Parzer ◽

Alexandra Kautzky-Willer

Keyword(s):

Diabetes Mellitus ◽

Insulin Resistance ◽

Type 2 Diabetes ◽

Gestational Diabetes ◽

Glucose Tolerance ◽

Gestational Diabetes Mellitus ◽

Mean Value ◽

High Risk Population ◽

Significant Difference

Abstract Introduction Secretagogin (SCGN) is a calcium binding protein related to insulin release in the pancreas. Although SCGN is not co-released with insulin, plasma concentrations have been found to be increased in type 2 diabetes mellitus patients.1,2,3 Up to this day, no study on SCGN levels in patients with gestational diabetes mellitus (GDM) has been published. Patients and Methods In 138 women of a high-risk population for GDM at the Medical University of Vienna, secretagogin levels of GDM patients were compared to women with a normal glucose tolerance (NGT). Glucose tolerance, insulin resistance and secretion were assessed with an oral glucose tolerance test (oGTT) performed before 20 weeks gestation. The women with GDM (39.1%) were further divided into GDM types depending on insulin sensitivity or secretion defects defined as below the 25th percentile in the oGTT of the NGT controls. Results Compared to women with NGT (mean SCGN= 52.7 ng/dl), there was no statistically significant difference in SCGN in patients with GDM (mean value 53.9 ng/dl, p=0.857). After splitting into secretion defect and insulin resistance subtypes, SCGN remained unrelated to GDM in our study population. However, Secretagogin was found to be significantly higher in postpartum visits (mean= 62.9 ng/dl) than during pregnancy (mean value= 48.5 ng/dl; p= 0.047). Furthermore, SCGN was positively correlated with BMI (p=0.006) in the present analysis. Conclusion Unlike in studies conducted on type 2 diabetes,1,2,3 a relationship between GDM and Secretagogin levels could not be demonstrated in this study. However, lower levels during pregnancy point towards physiological changes in SCGN levels unrelated to (gestational) diabetes mellitus. Further research, ideally including before-pregnancy levels, is paramount to assess possible roles of SCGN during pregnancy. 1. Maj M, Wagner L, Tretter V, et al. A TRPV1-to-secretagogin regulatory axis controls pancreatic β-cell survival by modulating protein turnover. EMBO J. 2017;36(14):2107-2125. doi:10.15252/embj.201695347 2. Yang C, Qu H, Zhao X, et al. Plasma Secretagogin is Increased in Individuals with Glucose Dysregulation. Exp Clin Endocrinol Diabetes. 2019:0-4. doi:10.1055/a-1001-2244 3. Maj M, Wagner L, Tretter V. 20 Years of Secretagogin: Exocytosis and Beyond. Front Mol Neurosci. 2019;12(February):1-10. doi:10.3389/fnmol.2019.00029

Download Full-text

Exploring Nutritype Signature of Type 2 Diabetes Risks in Women Post-Gestational Diabetes Mellitus

Case Medical Research ◽

10.31525/ct1-nct04190199 ◽

2019 ◽

Author(s):

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Gestational Diabetes ◽

Gestational Diabetes Mellitus

Download Full-text

Diet and Nutritional Interventions with the Special Role of Myo-Inositol in Gestational Diabetes Mellitus Management. An Evidence-Based Critical Appraisal

Current Pharmaceutical Design ◽

10.2174/1381612825666190722155512 ◽

2019 ◽

Vol 25 (22) ◽

pp. 2467-2473 ◽

Cited By ~ 1

Author(s):

Enrique Reyes-Muñoz ◽

Federica Di Guardo ◽

Michal Ciebiera ◽

Ilker Kahramanoglu ◽

Thozhukat Sathyapalan ◽

...

Keyword(s):

Diabetes Mellitus ◽

Gestational Diabetes ◽

Gestational Diabetes Mellitus ◽

Metabolic Diseases ◽

Nutritional Intervention ◽

Attractive Alternative ◽

Special Role ◽

Dose Frequency ◽

Nutritional Interventions

Background: Gestational Diabetes Mellitus (GDM), defined as glucose intolerance with onset or first recognition during pregnancy, represents one of the most common maternal-fetal complications during pregnancy and it is associated with poor perinatal outcomes. To date, GDM is a rising condition over the last decades coinciding with the ongoing epidemic of obesity and Type 2 Diabetes Mellitus (T2DM). Objective: The aim of this review is to discuss the role of diet and nutritional interventions in preventing GDM with the explanation of the special role of myo-inositol (MI) in this matter. Methods: We performed an overview of the most recent literature data on the subject with particular attention to the effectiveness of diet and nutritional interventions in the prevention of GDM with the special role of MI. Results: Nutritional intervention and physical activity before and during pregnancy are mandatory in women affected by GDM. Moreover, the availability of insulin-sensitizers such as different forms of inositol has dramatically changed the scenario, allowing the treatment of several metabolic diseases, such as those related to glucose dysbalance. Although the optimal dose, frequency, and form of MI administration need to be further investigated, diet supplementation with MI appears to be an attractive alternative for the GDM prevention as well as for the reduction of GDM-related complications. Conclusion: More studies should be conducted to prove the most effective nutritional intervention in GDM. Regarding the potential effectiveness of MI, further evidence in multicenter, randomized controlled trials is needed to draw firm conclusions.

Download Full-text

Thyroid Dysfunction in Pregnant Women with Gestational Diabetes Mellitus

Current Diabetes Reviews ◽

10.2174/1573399816666191223111833 ◽

2020 ◽

Vol 16 (8) ◽

pp. 895-899 ◽

Cited By ~ 1

Author(s):

Shahin Safian ◽

Farzaneh Esna-Ashari ◽

Shiva Borzouei

Keyword(s):

Diabetes Mellitus ◽

Gestational Diabetes ◽

Gestational Diabetes Mellitus ◽

Pregnant Women ◽

Thyroid Dysfunction ◽

Control Group ◽

Thyroid Peroxidase ◽

Free T4 ◽

Significant Difference ◽

Experimental Group

Aims: Investigation thyroid dysfunction and autoimmunity in pregnant women with gestational diabetes mellitus. Background: This article was written to evaluate the thyroid function and anti-thyroid peroxidase (anti- TPO) antibodies in pregnant women with gestational diabetes mellitus (GDM). Method: A total of 252 women with GDM and 252 healthy pregnant women were enrolled. Thyroid tests, including TSH, FreeT3, Free T4, and anti-TPO were performed for all women at 24–28 weeks of gestation. Data analysis was then carried out using SPSS ver. 22. Result: There was a significant difference between the experimental group (38.4%) and the control group (14.06%) in terms of the prevalence of subclinical hypothyroidism (p= 0.016). The frequency of anti-TPO was higher in the experimental group than the control group and positive anti-TPO was observed in 18.6% of women with GDM and 10.3% of healthy pregnant women (P= 0.008). Conclusion: Thyroid disorders are observed in pregnant women with GDM more frequently than healthy individuals and it may be thus reasonable to perform thyroid tests routinely.

Download Full-text